Mereo BioPharma Group plc
MREO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $10 | $0 | $49 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $3 | -$0 | $24 |
| Gross Profit | $0 | $7 | $0 | $25 |
| % Margin | – | 74.3% | – | 50.9% |
| R&D Expenses | $21 | $17 | $31 | $32 |
| G&A Expenses | $26 | $18 | $0 | $22 |
| SG&A Expenses | $26 | $18 | $23 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $47 | $36 | $54 | $53 |
| Operating Income | -$47 | -$28 | -$54 | -$28 |
| % Margin | – | -284.2% | – | -57.4% |
| Other Income/Exp. Net | $4 | -$2 | $9 | $47 |
| Pre-Tax Income | -$43 | -$30 | -$44 | $19 |
| Tax Expense | $0 | -$1 | -$2 | $2 |
| Net Income | -$43 | -$29 | -$42 | $17 |
| % Margin | – | -294.7% | – | 34.9% |
| EPS | -0.29 | -1,100.22 | -1,750.35 | 749.65 |
| % Growth | 100% | 37.1% | -333.5% | – |
| EPS Diluted | -0.29 | -1,100.22 | -1,750.35 | 749.65 |
| Weighted Avg Shares Out | 148 | 132 | 121 | 117 |
| Weighted Avg Shares Out Dil | 148 | 132 | 121 | 117 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $1 | $0 |
| Interest Expense | $1 | $3 | $3 | $5 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$41 | -$26 | -$40 | $25 |
| % Margin | – | -260.6% | – | 51.8% |